The Hall-Perrine Cancer Center and Mercy Urology Clinic teamed up with the Cedar Rapids Kernels for the third year in a row on to celebrate prostate cancer surv ...

Prostate cancer is known for being a "slow grower," meaning it often develops gradually without a dramatic onset. That’s why so many men ignore the early signs or confuse them with aging, diet ...

In recognition of Men’s Health Month, the University of Virginia (UVA) Cancer Center is expanding its “Stay in the Game” program, a vital community-centered initiative dedicated ...

Researchers at the University of Michigan Rogel Cancer Center identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form.

It’s a bad day when a doctor says you have cancer. It’s a worse day when he says it’s stage prostate cancer with a metastatic lesion. FDA approves updated labeling for Talzenna plus Xtandi in men with ...

More than half of prostate cancer survivors develop this condition following treatment. Nocturia has correlative links to several treatments commonly used for prostate cancer treatment. Surgical ...

Jay Harris, one of the anchors for ESPN's "SportsCenter," said on Thursday that he was recently diagnosed with prostate cancer and will have surgery to deal with it.

He was later diagnosed with prostate cancer, despite feeling healthy and active, and received a follow-up prostate-specific antigen (PSA) blood test in April, which confirmed the diagnosis.

Prostate and bladder cancer in men can be prevented with the right lifestyle practices. Around Father's Day 2025 is a good time to learn such tips. Monday, Jun 23, 2025. New Delhi o C.

Harris reiterated that he wanted to have more open conversations about prostate cancer and raise awareness about it. “We need to get the message out,” he continued. “People need to know.

Treatment for prostate cancer. Your treatment depends on a number of factors. These include how far the cancer has grown, whether it has spread anywhere else in your body and your general health. A ...

Johnson & Johnson has shared more data on its multifront attack on KLK2, linking a bispecific antibody to 7.9 months progression-free survival in hard-to-treat prostate cancer patients as it plans ...